I’m not sure if the flibanserin briefing docs are net bullish or net bearish for LibiGel. The absence of off-label competition from flibanserin is bullish, but the overall tenor of the briefing docs vis-à-vis the FSDD indication might be construed as bearish for LibiGel’s chances of gaining approval.
BPAX closed about flat for the day.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”